News
EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical stage biopharmaceutical company ...
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback